Value proposition

First-of-its-kind antigen modulation to address immune dysfunction in oncology and autoimmunity.

Next generation therapeutic approach for immuno-oncology & autoimmune diseases.

Grey Wolf was founded by leading scientists, drug developers and investors committed to translating the broad therapeutic potential of ERAP-driven antigen modulation into next generation therapies for patients with immunologically-driven diseases.

We are a clinical-stage, UK- and Australia-based drug discovery and development company spearheading a new therapeutic strategy based on a first-of-its-kind approach to antigen modulation. Our innovative technology is centered on inhibiting the endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2), which play a central role in the antigen presentation pathway. We leverage its leadership in the area of ERAP inhibition and antigen modulation to advance novel therapeutic approaches to address the source of immune dysfunction in oncology and autoimmunity.

Rather than targeting the immune system, our approach is to directly alter the tumour cells, illuminating them for attack and destruction by the immune system.

We are targeting a key protein in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells, thus dramatically increasing tumour visibility and extending the reach of immunotherapy in oncology.

Grey Wolf is working with leading academic and commercial drug discovery partners to deliver a clinical candidate against a strongly validated target. The Grey Wolf team is made up of experts in immuno-oncology, antigen presentation and drug discovery.

For more information, visit the website or email enquiries@gwt.bio.